We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : ajtj's Post-Lobotomy Market Charts and Thoughts
BRKA 315,375.00Oct 20 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tntpal who wrote (37942)9/26/2021 11:57:49 AM
From: Jacob Snyder2 Recommendations

Recommended By

  Read Replies (1) of 67690
JNJ: Of it’s 3 divisions, the only one growing is pharma. There is a global movement by governments to force lower drug prices. This is happening in Europe and China, but not yet in the US. When it comes here (our version of Common Prosperity), JNJ will have a much lower PE than the current 25. I will wait to buy pharma till then. The timing on this is uncertain, but the trend is clear. The market is only starting to price this risk in.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext